PD-1 Blockade Combined with Heated Intraperitoneal Chemotherapy Improves Outcome in Experimental Peritoneal Metastases from Colonic Origin in a Murine Model

Background Heated intraperitoneal chemotherapy (HIPEC) was shown to induce immunogenicity of peritoneal metastases from colorectal cancer (PM-CRC) by induction of immunogenic cell death. We aimed to explore whether the addition of a checkpoint inhibitor would augment the effect of HIPEC in an experi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2023-05, Vol.30 (5), p.2657-2663
Hauptverfasser:	Geva, Ravit, Alon, Gilad, Nathanson, Maya, Bar-David, Shoshi, Nevo, Nadav, Aizic, Asaf, Peles-Avraham, Sharon, Lahat, Guy, Nizri, Eran
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antineoplastic Combined Chemotherapy Protocols Apoptosis CD20 antigen CD8 antigen Cell death Chemotherapy Colon cancer Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - pathology Combined Modality Therapy Cytoreduction Surgical Procedures - methods Disease Models, Animal Gastric cancer Heat shock proteins Hyperthermia, Induced - methods Immune checkpoint inhibitors Immune response Immunogenicity Infiltration Inoculation Medicine Medicine & Public Health Metastases Metastasis Mice Mice, Inbred C57BL Mitomycin - therapeutic use Mitomycin C Oncology PD-1 protein Peritoneal diseases Peritoneal Neoplasms - secondary Peritoneal Surface Malignancy Peritoneum Programmed Cell Death 1 Receptor Protein folding Surgery Surgical Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Heated intraperitoneal chemotherapy (HIPEC) was shown to induce immunogenicity of peritoneal metastases from colorectal cancer (PM-CRC) by induction of immunogenic cell death. We aimed to explore whether the addition of a checkpoint inhibitor would augment the effect of HIPEC in an experimental murine model of PM-CRC. Methods PM-CRC was established in C57BL mice by intraperitoneal inoculation of MC38 colon cancer cells. HIPEC was administered using the closed technique with mitomycin C (MMC). Clinical and immunological parameters were compared between animals treated with HIPEC alone and those treated with HIPEC + anti-programmed death receptor-1 (aPD-1). Results MMC-based HIPEC increased the overall survival of animals compared with sham-treated animals (22.8; 95% confidence interval [CI] 21.14–24.53 vs. 18.9 days; 95% CI 17.6–20.3, p
ISSN:	1068-9265 1534-4681
DOI:	10.1245/s10434-022-13025-7